Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$333.45 USD

333.45
331,765

-0.35 (-0.11%)

Updated Oct 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (190 out of 252)

Industry: Medical Services

Better trading starts here.

Zacks News

Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Medpace (MEDP)

The heavy selling pressure might have exhausted for Medpace (MEDP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Medpace (MEDP) Q4 Earnings Beat Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 5.60% and 0.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic (HOLX) to Meet High Testing Demand With Panther Trax

Hologic's (HOLX) Panther Trax scalable solutions will meet the needs of today's laboratories, enabling them to expand operational capacity and testing volumes.

Integra (IART) Businesses Rebound Despite Supply Issues

Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.

Medtronic (MDT) Businesses Rebound Amid Raging Pandemic

Medtronic (MDT) is registering strong organic growth in the Cardiovascular, Neuroscience and Diabetes segments on product launches.

Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod

Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.

Here's Why You Should Retain Haemonetics (HAE) Stocks for Now

Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.

Medtronic's (MDT) INVOS System Gets FDA 510 (k) Clearance

Medtronic's (MDT) INVOS 7100 system can deliver key signals to pediatric clinicians for making time-sensitive decisions

Here's Why You Should Retain STERIS (STE) Stock for Now

Investors are optimistic about STERIS (STE) owing to strong segmental growth and bullish 2022 outlook.

NEOGEN (NEOG) Gains on 3M's Food Safety Arm Merger Deal

According to NEOGEN (NEOG), apart from the United States and Europe, substantial interest among developing nations to improve food safety presents significant growth potential for the combined company.

Walgreens (WBA), Village MD Plan to Expand Into San Antonio

Walgreens (WBA) and VillageMD to improve access to overall care for patients with chronic conditions by opening nine new Village Medical at Walgreens primary care practices in San Antonio.

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.

Here's Why You Should Retain Charles River (CRL) Stock for Now

Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.

Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses

Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.

Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm

The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.

CVS Health (CVS) Outlines Growth Strategy, Initiates 2022 View

CVS Health's (CVS) new strategy capitalizes on the considerable opportunity to make health care more convenient, personalized and affordable for consumers.

Edwards (EW) States Long-Term Strategy, Provides 2022 View

Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.

Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test

Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.

QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

Exact Sciences' (EXAS) Oncotype DX Test Study Data Favorable

Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors are optimistic about QIAGEN (QGEN) on strong third-quarter results and raised 2021 guidance.

Here's Why You Should Retain Tandem Diabetes (TNDM) for Now

Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.

Medpace Holdings (MEDP) Sees Hammer Chart Pattern: Time to Buy?

Medpace Holdings (MEDP) has been struggling lately, but the selling pressure may be coming to an end soon.